STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
197
13F, latest reported quarter
Conversions, 180 days
45
Codes C/M, not in net · $0 priced
What the filings say about HNGE
Insiders, 180 days
-$392.0M net sold
9 sellers · 27% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$444.9M
28 notices
Hinge Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Hinge Health, Inc. insiders sold a net $392.0M of stock across 182 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Sep 14, 2026.
The trade is 4.5% of the 191,358 shares held after it.
3 other insiders sold within 30 days.
197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mecklenburg Gabriel M.I. sold about $877.4K of HNGE under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.
34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Sep 14, 2026.
The trade is 91.6% of the 99,856 shares held after it.
3 other insiders sold within 30 days.
197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mecklenburg Gabriel M.I. sold about $9.4M of HNGE under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.
34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Sep 14, 2026.
The trade is 150.5% of the 39,868 shares held after it.
3 other insiders sold within 30 days.
197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mecklenburg Gabriel M.I. sold about $6.2M of HNGE under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.
34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Sep 14, 2026.
3 other insiders sold within 30 days.
197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mecklenburg Gabriel M.I. sold about $4.2M of HNGE under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.
22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Sep 10, 2026.
The trade is 0.6% of the 342,348 shares held after it.
3 other insiders sold within 30 days.
197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Budge James sold about $213.2K of HNGE under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.
182 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
HNGE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Insight Venture Partners (Cayman) X, L.P.
Filed 2026-10-14
$64.5M
Insight Venture Partners X, L.P.
Filed 2026-10-14
$78.7M
Insight Venture Partners (Delaware) X, L.P.
Filed 2026-10-14
$12.5M
Insight Venture Partners X (Co-Investors), L.P.
Filed 2026-10-14
$1.9M
JAMES BUDGE
Filed 2026-10-13
$4.9M
HNGE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AVE MARIA WORLD EQUITY FUND
$4.9M position · as of 2026-06-30
3.1%
Royce Smaller-Companies Growth Fund
$7.3M position · as of 2026-06-30
3.0%
CapForce IBD 50 ETF
$2.3M position · as of 2026-07-31
2.9%
LISANTI SMALL CAP GROWTH FUND
$464.4K position · as of 2026-06-30
2.5%
Meridian Growth Fund
$12.4M position · as of 2026-06-30
2.3%
Meridian Small Cap Growth Fund
$6.2M position · as of 2026-06-30
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Not applicable
3 active
What changed recently
A Comprehensive Digital Care Program for Migraine Management
2026-09-18 · Recruiting → Enrolling By Invitation
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $392.0M sold by insiders over 180 days, 197 funds added last quarter, $444.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$720.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HNGE
FY Dec 2025
$587.9M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$212.8M
Mar 2026
$182.3M
Dec 2025
$170.7M
Sep 2025
$154.2M
Jun 2025
$139.1M
Mar 2025
$123.8M
Dec 2024
$117.3M
Sep 2024
$100.6M
At each fiscal year end
Single quarter
Net margin, TTM
+15.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HNGE
FY Dec 2025
-89.9%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+20.5%
Mar 2026
+19.3%
Dec 2025
+18.8%
Sep 2025
-1.2%
Jun 2025
-413.8%
Mar 2025
+13.8%
Dec 2024
+23.1%
Sep 2024
+0.3%
At each fiscal year end
Single quarter
Free cash flow, TTM
$290.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HNGE
FY Dec 2025
$170.7M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$101.3M
Mar 2026
$43.0M
Dec 2025
$63.5M
Sep 2025
$82.3M
Jun 2025
$20.0M
Mar 2025
$4.9M
Dec 2024
$38.2M
Sep 2024
$28.1M
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+42.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+42.1%
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HNGE
FY Dec 2025
-74.5%
FY Dec 2024
-1.8%
FY Dec 2023
n/a
Jun 2026
+14.3%
Mar 2026
-70.0%
Dec 2025
-74.5%
Sep 2025
-69.3%
Jun 2025
-76.6%
Mar 2025
+4.7%
Dec 2024
-1.8%
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+25.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HNGE
FY Dec 2025
-135.5%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+25.8%
Mar 2026
-167.8%
Dec 2025
-135.5%
Sep 2025
-133.9%
Jun 2025
-145.0%
Mar 2025
+3.0%
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
36.93x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
27.48x
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing HNGE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
HNGE ranks highest on profitability (90th percentile) and growth (85th), and lowest on insider conviction (2nd), among Software & IT peers.
Profitability
90
Inputs
Return on equity+42.1% · 90 pct, sector of 286
Return on assets+14.3% · 87 pct, sector of 381
Return on invested capitalno debt line filed
Return on capital employed+25.8% · 92 pct, sector of 294
Growth
85
Inputs
Revenue growth, YoY+50.6% · 85 pct, sector of 480
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
2
Inputs
Net Form 4 buying (codes P and S), 180d-$299.3M · 3 pct, sector of 285
Insider buyers, 180d0 · 0 pct, sector of 290
Institutional and government
75
Inputs
Funds adding, latest quarter197 · 75 pct, sector of 415
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
18
Inputs
Short interest, % of float+12.5% · 18 pct, sector of 530
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Financial health, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HNGE filings, in plain words
Are Hinge Health insiders buying or selling HNGE?
In the 180 days to 2026-10-27, Hinge Health insiders were net sellers, a net $392.0M across purchases and sales reported on Form 4, by 9 sellers.
Are there planned insider sales of HNGE?
Yes. 28 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $444.9M of stock; the latest, by Insight Venture Partners (Cayman) X, L.P., was filed 2026-10-14.
Read the full summary
In the 180 days to 2026-10-27, Hinge Health insiders were net sellers of HNGE, a net $392.0M across purchases and sales reported on Form 4 by 9 sellers. Most of that figure, $295.6M, came from a holder of 10% or more rather than an officer or director. 27% of the 139 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 28 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $444.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.